Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Abstract Background Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (Onco...

Descripció completa

Dades bibliogràfiques

Autors principals:	Beate Jahn, Ursula Rochau, Christina Kurzthaler, Michael Hubalek, Rebecca Miksad, Gaby Sroczynski, Mike Paulden, Marvin Bundo, David Stenehjem, Diana Brixner, Murray Krahn, Uwe Siebert
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2017-10-01
Col·lecció:	BMC Cancer
Matèries:	Cost-effectiveness analysis Breast cancer Adjuvant chemotherapy Adjuvant!Online OncotypeDX Discrete event simulation
Accés en línia:	http://link.springer.com/article/10.1186/s12885-017-3603-z
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!